Berlin Cures Patent for BC 007

News related to COVID and Gq/11
Post Reply
admin
Site Admin
Posts: 4357
Joined: Tue Jan 18, 2005 10:25 pm

Berlin Cures Patent for BC 007

Post by admin »

The patent by Berlin Cures that describes the aptamer under consideration for treatment in Long Covid can be found here:

"APTAMERS FOR USE IN THE TREATMENT OF CORONAVIRIDAE INFECTIONS"
WO2021205012 (A1) ― 2021-10-14
https://worldwide.espacenet.com/publica ... cale=en_EP

"In a preferred embodiment of the second aspect, the disease symptoms comprise one or more from the group comprising neurological symptoms, such as chronic fatigue syndrome, postural orthostatic tachycardia syndrome (PoTS), dysautonomia, tremor, attention deficit, anomic aphasia, neuropathy, transverse myelitis, acute necrotising myelitis, and Guillain-Barre syndrome, cardiovascular symptoms, such as myocardial inflammation, arrhythmia, tachycardia, bradycardia, hypertension, and atrioventricular (AV) block, dermatological symptoms, such as alopecia and eczema, or gastrointestinal diseases.

In another preferred embodiment of the second aspect of the present invention, the aptamer is used to inhibit the interaction of autoantibodies specific for a G-protein coupled receptor with its target proteins.

In yet another preferred embodiment of the second aspect of the present invention, the aptamer is for use in the treatment of a patient in which autoantibodies against G-protein coupled receptors can be detected.

In one preferred embodiment of the second aspect of the present invention, the patient exhibits functional autoantibodies against G-protein coupled receptors, preferably functional autoantibodies specific for any one of the human G-protein coupled receptor adrenergic alpha-1 receptor, adrenergic beta-2 receptor, endothelin 1 ETA receptor, muscarinic M2receptor, angiotensin II AT1 receptor, MAS-receptor and/or the nociception receptor, more preferably for any one of the adrenergic beta-2 receptor, muscarinic M2receptor, angiotensin II AT1 receptor, MAS-receptor, particularly preferably wherein the patient exhibits an antibody pattern comprising functional autoantibodies specific for each of the adrenergic beta-2 receptor, muscarinic M2receptor, angiotensin II AT1 receptor, and MAS-receptor."

================
"Two of the identified GPCR-fAABs, observed in over 90% of the investigated COVID-19 patient sera (23/25), were directed against receptors of RAS, namely the angiotensin II AT1 receptor and the angiotensin (1-7) MAS receptor. These vasoactive AT1-fAABs had been identified before in patients with malignant hypertension, therapy-resistant hypertension, preeclampsia, and kidney diseases."
Post Reply